Therapeutic potential of siRNA and DNAzymes in cancer

Karnati, Hanuma Kumar; Yalagala, Ravi Shekar; Undi, Ram Babu; Pasupuleti, Satya Ratan; Gutti, Ravi Kumar

doi:10.1007/s13277-014-2477-9

Cited by 30 publications

(20 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to ribozymes, DNAzymes are more cost-effective, easier to synthesis, more stable and can be easily labeled, presenting a better candidate for such applications. So far, DNAzymes have showed potential as therapeutic agents for various diseases, such as antiviral, antibacterial, anti-cancer and anti-inflammatory 58-60, as well as atherosclerosis 61. DNAzyme was initially tested for the HIV RNA cleavage in vitro 20.…”

Section: Cleaving Rna For Therapeutic Applicationsmentioning

confidence: 99%

Theranostic DNAzymes

Zhou¹,

Ding²,

Liu³

2017

Theranostics

209

145

View full text Add to dashboard Cite

DNAzymes are catalytically active DNA molecules that are obtained via in vitro selection. RNA-cleaving DNAzymes have attracted significant attention for both therapeutic and diagnostic applications due to their excellent programmability, stability, and activity. They can be designed to cleave a specific mRNA to down-regulate gene expression. At the same time, DNAzymes can sense a broad range of analytes. By combining these two functions, theranostic DNAzymes are obtained. This review summarizes the progress of DNAzyme for theranostic applications. First, in vitro selection of DNAzymes is briefly introduced, and some representative DNAzymes related to biological applications are summarized. Then, the applications of DNAzyme for RNA cleaving are reviewed. DNAzymes have been used to cleave RNA for treating various diseases, such as viral infection, cancer, inflammation and atherosclerosis. Several formulations have entered clinical trials. Next, the use of DNAzymes for detecting metal ions, small molecules and nucleic acids related to disease diagnosis is summarized. Finally, the theranostic applications of DNAzyme are reviewed. The challenges to be addressed include poor DNAzyme activity under biological conditions, mRNA accessibility, delivery, and quantification of gene expression. Possible solutions to overcome these challenges are discussed, and future directions of the field are speculated.

show abstract

Section: Cleaving Rna For Therapeutic Applicationsmentioning

confidence: 99%

Theranostic DNAzymes

Zhou¹,

Ding²,

Liu³

2017

Theranostics

209

145

View full text Add to dashboard Cite

show abstract

“…The endonucleolytic DNAzyme motif substation in LNA-based anti-miRNAs and in siRNA could enhance their silencing ability, in addition to their stability [161, 162]. Several factors, such as dosage, duration of activity and clearance of anti-miRNA molecules, need to be evaluated before successful miRNA delivery to target sites in in vivo models of neurodegeneration is achieved.…”

Section: Therapeutic Role Of Mirnas In Neurodegenerative Diseases mentioning

confidence: 99%

miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy

Karnati

Panigrahi

Gutti

et al. 2015

JAD

Self Cite

110

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are endogenous, ~22 nucleotide, non-coding RNA molecules that function as post-transcriptional regulators of gene expression. miRNA dysregulation has been observed in cancer and in neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Amyotrophic lateral sclerosis (ALS) and the neurological disorder, epilepsy. Neuronal degradation and death are important hallmarks of neurodegenerative disorders. Additionally, abnormalities in metabolism, synapsis and axonal transport have been associated with AD, PD and frontotemporal dementia (FTD). A number of recently published studies have demonstrated the importance of miRNAs in the nervous system and have contributed to the growing body of evidence on miRNA dysregulation in neurological disorders. Knowledge of the expressions and activities of such miRNAs may aid in the development of novel therapeutics. In this review, we discuss the significance of miRNA dysregulation in the development of neurodegenerative disorders and the use of miRNAs as targets for therapeutic intervention.

show abstract

“…RNA interference (RNAi) is a process that targets specific mRNAs for degradation, thereby abrogating expression of the encoded proteins. Synthetic RNAi derivatives, such as short interfering RNAs (siRNA), were shown to be effective therapeutics against several genetic diseases, cancers and viral infections . ALN‐RSV01 is an siRNA directed against the RSV nucleocapsid (N) protein .…”

Section: Results Of Searchmentioning

confidence: 99%

Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials

Broadbent

Shields

Power

2015

Influenza Resp Viruses

View full text Add to dashboard Cite

As the most important viral cause of severe respiratory disease in infants and increasing recognition as important in the elderly and immunocompromised, respiratory syncytial virus (RSV) is responsible for a massive health burden worldwide. Prophylactic antibodies were successfully developed against RSV. However, their use is restricted to a small group of infants considered at high risk of severe RSV disease. There is still no specific therapeutics or vaccines to combat RSV. As such, it remains a major unmet medical need for most individuals. The World Health Organisations International Clinical Trials Registry Platform (WHO ICTRP) and PubMed were used to identify and review all RSV vaccine, prophylactic and therapeutic candidates currently in clinical trials. This review presents an expert commentary on all RSV-specific prophylactic and therapeutic candidates that have entered clinical trials since 2008.

show abstract

Therapeutic potential of siRNA and DNAzymes in cancer

Cited by 30 publications

References 164 publications

Theranostic DNAzymes

Theranostic DNAzymes

miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy

Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials

Contact Info

Product

Resources

About